Wacker (WCH.DE)

Executive Summary

Wacker Chemie AG, a German multinational specialty chemicals company headquartered in Munich, has evolved from its 1914 origins into a global leader in silicones, polymers, and biotech solutions. With a significant focus on its Contract Development and Manufacturing Organization (CDMO) for biologics and nucleic acids, the company serves over 100 countries. Its biologics CDMO segment, particularly in antibodies and synthetic biology, positions it to benefit from the growing demand for complex therapeutic modalities. While the core chemical business provides stable cash flows, the biotech arm offers higher growth potential, though competition and cyclicality in chemicals remain risks. The company's established track record and diversified portfolio underpin a resilient business model, but near-term growth catalysts are incremental rather than transformative.

Upcoming Catalysts (preview)

• H2 2026Completion of Biologics CDMO Facility Expansion in Munich80% success
• Q4 2026New Strategic Partnership for mRNA Manufacturing60% success
• 2027Launch of Next-Generation Biosimilar Pipeline40% success